Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline
MT Newswires Live
Aug 14
Zentalis Pharmaceuticals (ZNTL) priced an offering of 23 million shares at $3.50 each, targeting about $80.5 million in gross proceeds, the company said late Thursday.
The company granted underwriters a 30-day option to purchase up to an additional 3.45 million shares.
Net proceeds, together with existing cash, cash equivalents and marketable securities, are intended to finance, among other things, clinical trials, preclinical studies, and regulatory filings.
Zentalis is selling all of the common stock in the offering, which is expected to close on Aug. 17.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.